Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
Piscopo, Anthony, Chowdhury, Ajmain , Teferi, Nahom , Lee, Sarah , Challa, Meron, Eschbacher, Kathryn L. , Petronek, Michael S. , Bathla, Girish , Buatti, John M. , Hitchon, Patrick W.

Mayo Clinic

Neurosurgery | September 25, 2023 | Volume: 94 | Issue: 2 | Pages: 358-368

10.1227/neu.0000000000002692 | PMID 37747216 Get It

BACKGROUND AND OBJECTIVES: Meningeal solitary fibrous tumors (SFTs) comprise 0.4% of primary central nervous system neoplasms and carry metastatic potential. Disease course and optimal management are largely unknown, and there is currently no literature rigorously describing neurological outcomes in surgically managed SFTs. We present one of the largest craniospinal SFT series, analyze patient outcomes, and extensively review the associated literature. METHODS: All surgically managed SFTs at our institution between January 2005 and March 2023 were retrospectively reviewed. Patient demographics, tumor and radiographic features, treatment, and clinical outcomes were collected. Neurological function was quantified using Frankel grade and Neurologic Assessment in Neuro-Oncology scores. Descriptive statistics, multivariate analysis, log-rank test, and Kaplan–Meier survival analysis were performed. RESULTS: Twenty-one patients satisfied inclusion criteria. Tumor locations included 15 supratentorial, three infratentorial, and three spinal. All patients underwent surgical resection, and 16 (76.2%) underwent radiation. Six (28.6%) patients had tumor recurrence, and three (14.3%) developed metastasis. Younger age and higher postoperative Frankel grade were significantly associated with increased overall survival (OS) ( P = .011, P = .002, respectively). All patients symptomatically improved or stabilized after surgery, and Neurologic Assessment in Neuro-Oncology score ( P = .001) and functional status significantly improved postoperatively (Karnofsky Performance Status: 65.2 ± 25.2 vs 91.4 ± 13.5, P = .001). Sex, adjuvant radiation, and extent of resection were not significantly associated with OS. CONCLUSION: SFT of the central nervous system is a rare entity with a variable clinical course. Surgical resection was associated with improved postoperative functional and neurological status. Higher postoperative neurological function was significantly associated with OS. Further studies are warranted to validate a standardized treatment algorithm and investigate the efficacy of adjuvant radiation in SFT.
Statistical Mechanics Metrics in Pairing and Parsing In Silico and Phenotypic Data of a Novel Genetic NFκB1 (c.T638A) Variant
Chaudhri, Eman N. , Abbott, Jessica M. , Islam, Naeyma N., Weber, Caleb A., Coban, Matt , Squire, Jacqueline D. , Mantia, Sarah, Wierenga, Klaas J. , Caulfield, Thomas R. , Coban, Mathew A , Bilgili, Ahmet , Caulfield, Thomas R , Abbott, Jessica M., Squire, Jacqueline , Fuller, Jessica M.

Mayo Clinic

Genes | September 24, 2023 | Volume: 14 | Issue: 10 | Pages: 1855

10.3390/genes14101855 | PMID 37895204 Get It

(1) Background: Mutations in NFκB1, a transcriptional regulator of immunomodulating proteins, are a known cause of inborn errors of immunity. Our proband is a 22-year-old male with a diagnosis of common variable immunodeficiency (CVID), cytopenias with massive splenomegaly, and nodular regenerative hyperplasia of the liver. Genetic studies identified a novel, single-point mutation variant in NFκB1, c. T638A p. V213E. (2) Methods: Next-generation panel sequencing of the patient uncovered a novel single-point mutation in the NFκB1 gene that was modeled using the I-TASSER homology-modeling software, and molecular dynamics were assessed using the YASARA2 software (version 20.14.24). (3) Results: This variant replaces valine with glutamic acid at position 213 in the NFκB1 sequence. Molecular modeling and molecular dynamic studies showed altered dynamics in and around the rel homology domain, ankyrin regions, and death domain of the protein. We postulate that these changes alter overall protein function. (4) Conclusions: This case suggests the pathogenicity of a novel variant using protein-modeling techniques and molecular dynamic simulations.
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network
Wagemann, Olivia , Li, Yan , Hassenstab, Jason , Aschenbrenner, Andrew J. , Gordon, Brian A. , Xiong, Chengjie , Perrin, Richard J. , Berman, Sarah , Chhatwal, Jasmeer P. , Farlow, Martin R. , Day, Gregory S. , Mori, Hiroshi , Noble, James M. , Morris, John C. , Daniels, Alisha , Xiong, Chengjie , Network, the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Daniels, Alisha , Berman, Sarah , Noble, James M , McKay, Nicole S. , Benzinger, Tammie L.S. , Xiong, Chengjie , Cruchaga, Carlos , Renton, Alan , Ikeuchi, Takeshi , Jucker, Mathias , Lopera, Francisco Javier , Sánchez‐Valle, Raquel , Schofield, Peter R. , Bateman, Randall J. , McDade, Eric , Llibre‐Guerra, Jorge J. , Network, the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | September 23, 2023 | Volume: 20 | Issue: 1 | Pages: 47-62

10.1002/alz.13460 | PMID 37740921 Get It

AbstractINTRODUCTIONStudies suggest distinct differences in the development, presentation, progression, and response to treatment of Alzheimer's disease (AD) between females and males. We investigated sex differences in cognition, neuroimaging, and fluid biomarkers in dominantly inherited AD (DIAD).METHODSThree hundred twenty‐five mutation carriers (55% female) and one hundred eighty‐six non‐carriers (58% female) of the Dominantly Inherited Alzheimer Network Observational Study were analyzed. Linear mixed models and Spearman's correlation explored cross‐sectional sex differences in cognition, cerebrospinal fluid (CSF) biomarkers, Pittsburgh compound B positron emission tomography (11C‐PiB PET) and structural magnetic resonance imaging (MRI).RESULTSFemale carriers performed better than males on delayed recall and processing speed despite similar hippocampal volumes. As the disease progressed, symptomatic females revealed higher increases in MRI markers of neurodegeneration and memory impairment. PiB PET and established CSF AD markers revealed no sex differences.DISCUSSIONOur findings suggest an initial cognitive reserve in female carriers followed by a pronounced increase in neurodegeneration coupled with worse performance on delayed recall at later stages of DIAD.
Reflecting on Progress in and Establishing Benchmarks for Sex and Gender Health Education
Barr, Elizabeth , Chin, Eliza Lo, Rojek, Mary K., Sleeper, Rebecca B. , Temkin, Sarah M. , Clayton, Janine A. , Kantarci, Kejal , Kling, Juliana M. , McGregor, Alyson J. , Schiebinger, Londa , Viggiano, Thomas R., Wood, Susan F. , Werbinski, Jan, Temkin, Sarah M , Clayton, Janine A , Kantarci, Kejal , Kling, Juliana M , Schiebinger, Londa , Templeton, Kimberly , Newman, Connie B. , Templeton, Kimberly

Mayo Clinic

Academic Medicine | September 23, 2023 | Volume: 99 | Issue: 1 | Pages: 16-21

10.1097/acm.0000000000005444 | PMID 37734039 Get It

Abstract Sex and gender influence every aspect of human health; thus, sex- and gender-related topics should be incorporated in all aspects of health education curricula. Sex and gender health education (SGHE) is the rigorous, intersectional, data-driven integration of sex and gender into all elements of health education. A multisectoral group of thought leaders has collaborated to advance SGHE since 2012. This cross-sector collaboration to advance SGHE has been successful on several fronts, primarily developing robust interprofessional SGHE programs, hosting a series of international SGHE summits, developing sex- and gender-specific resources, and broadening the collaboration beyond medical education. However, other deeply entrenched challenges have proven more difficult to address, including accurate and consistent sex and gender reporting in research publications, broadening institutional support for SGHE, and the development and implementation of evaluation plans for assessing learner outcomes and the downstream effects of SGHE on patient care. This commentary reflects on progress made in SGHE over the first decade of the current collaboration (2012–2022), articulates a vision for next steps to advance SGHE, and proposes 4 benchmarks to guide the next decade of SGHE: (1) integrate sex, gender, and intersectionality across health curricula; (2) develop sex- and gender-specific resources for health professionals; (3) improve sex and gender reporting in research publications; and (4) develop evaluation plans to assess learner and patient outcomes.
Gastroenterology Clinic Follow-Up Reduces Gastroenterology-Specific Readmissions Among Patients With Severe Ulcerative Colitis
Barber, Grant E. , Justin, Zhuo, Okafor, Philip N. , Streett, Sarah E.

Mayo Clinic

Inflammatory Bowel Diseases | September 22, 2023 | Volume: 30 | Issue: 8 | Pages: 1319-1325

10.1093/ibd/izad207 | PMID 37738588 Get It

Abstract Background and aims Readmission within 30 days occurs in up to 18% of admitted patients with ulcerative colitis (UC). The importance of postdischarge follow-up with a gastroenterologist as well as the optimal follow-up interval is unknown. Methods We conducted a retrospective cohort study of patients with UC who were admitted to Stanford University Hospital between 2010 and 2020. We included adult patients with UC who were admitted for a UC flare. Patients with a colectomy during hospitalization or with Clostridium difficile infection at the index hospitalization were excluded. The primary outcome was time to readmission for a gastroenterology (GI) indication, and the primary predictor (time dependent) was follow-up with a GI provider. Patients were followed for 180 days after discharge. Data were analyzed using a Cox proportional hazards model. Results Of the 223 patients hospitalized with UC during the study period, 25% (n = 57) were readmitted within 180 days, with 13.9% occurring within 30 days. Early follow-up (within 7 days) was observed in 29% (n = 65) of patients, while 30-day follow-up was seen in 68.7% (n = 153), and follow-up within 180 days was seen in 198 (89%) patients. In the adjusted Cox proportional hazards model, GI follow-up was associated with fewer readmissions (hazard ratio, 0.42; 95% confidence interval, 0.22-0.81; P = .009). Early follow-up was strongly associated with a reduced risk of readmission (hazard ratio, 0.24; 95% 95% confidence interval, 0.09-0.69; P = .008). Follow-up in 7 days was associated with fewer readmissions (P < .0001). Conclusions Outpatient GI follow-up after UC hospitalization reduces readmissions, with the greatest reduction occurring among patients followed up within 1 week of discharge.
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
Qualls, David , Lambert, Nicholas , Caimi, Paolo F. , Merrill, Mwanasha H. , Pullarkat, Priyanka, Bond, David A. , Wehmeyer, Graham T. , Romancik, Jason T. , Amoozgar, Behzad , Leslie, Lori A. , Crombie, Jennifer L. , Khurana, Arushi , Nowakowski, Grzegorz S. , Maddocks, Kami J. , Rutherford, Sarah C. , Okwali, Michelle, Seshan, Venkatraman , Batlevi, Connie Lee , Qualls, David A , Merrill, Mwanasha , Bond, David A , Wehmeyer, Graham T , Romancik, Jason T , Nastoupil, Loretta J , Crombie, Jennifer L , Abramson, Jeremy S , Buege, Michael J , Seshan, Venkatraman , Batlevi, Connie L , Salles, Gilles A , Caimi, Paolo F , Godby, Richard , Nastoupil, Loretta J. , Abramson, Jeremy S. , Kahl, Brad S. , Buege, Michael J. , Salles, Gilles

Mayo Clinic

Blood | September 22, 2023 | Volume: 142 | Issue: 26 | Pages: 2327-2331

10.1182/blood.2023021274 | PMID 37738563 Get It

Abstract In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.
Impact of Climatic Factors on Varicella-Zoster Viral Infection
Dempsey, Sarah-Jane, Andersen, Louise K. , Coates, Sarah J. , Davis, Mark D. P. , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology and Venereology | September 21, 2023 | Volume: 8 | Issue: 1 | Pages: 61-62

10.1097/jd9.0000000000000347 Get It

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
Rahman, Rifaquat , Trippa, Lorenzo , Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Fell, Geoffrey, McCluskey, Christine , Wiley, Jennifer, Gaffey, Sarah, Welch, Mary , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Beroukhim, Rameen , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Mellinghoff, Ingo K. , Haas‐Kogan, Daphne A. , Tanguturi, Shyam , Cagney, Daniel , Aizer, Ayal A. , Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Geduldig, Jack , Watkinson, Fiona , Pisano, William , Ramkissoon, Shakti, Reardon, David A. , Wen, Patrick Y. , Touat, Mehdi , Welch, Mary R , Ahluwalia, Manmeet S , Colman, Howard , Nabors, Louis Burt , Chukwueke, Ugonma N , Nayak, Lakshmi , Batchelor, Tracy T , Kaley, Thomas , Lu-Emerson, Christine , Mellinghoff, Ingo K , Bi, Wenya Linda , Peruzzi, Pier Paolo , Haas-Kogan, Daphne , Aizer, Ayal , Geduldig, Jack , Pisano, William , Chiocca, E Antonio , Reardon, David A , Alexander, Brian M , Ligon, Keith L , Wen, Patrick Yung , Tanguturi, Shyam K , Arrillaga‐Romany, Isabel , Fell, Geoffrey G. , Drappatz, Jan , Galanis, Evanthia , Nabors, Burt , McFaline-Figueroa, J Ricardo , Arnaout, Omar M. , Malinowski, Seth W. , Santagata, Sandro , Meredith, David M. , Alexander, Brian M.

Mayo Clinic

Journal of Clinical Oncology | September 18, 2023 | Volume: 41 | Issue: 36 | Pages: 5524-5535

10.1200/jco.23.00493 | PMID 37722087 Get It

PURPOSE The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid–dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm. We report the results for each arm and examine the feasibility and conduct of the adaptive platform design. PATIENTS AND METHODS Patients with newly diagnosed O 6 -methylguanine–DNA methyltransferase-unmethylated glioblastoma were eligible if they had tumor genotyping to identify prespecified biomarker subpopulations of dominant glioblastoma signaling pathways (EGFR, phosphatidylinositol 3-kinase, and CDK). Initial random assignment was 1:1:1:1 between control (radiation therapy and temozolomide) and the experimental arms. Subsequent Bayesian adaptive randomization was incorporated on the basis of biomarker-specific progression-free survival (PFS) data. The primary end point was overall survival (OS), and one-sided P values are reported. The trial is registered with ClinicalTrials.gov (identifier: NCT02977780 ). RESULTS Two hundred thirty-seven patients were treated (71 control; 73 abemaciclib; 81 neratinib; 12 CC-115) in years 2017-2021. Abemaciclib and neratinib were well tolerated, but CC-115 was associated with ≥ grade 3 treatment-related toxicity in 58% of patients. PFS was significantly longer with abemaciclib (hazard ratio [HR], 0.72; 95% CI, 0.49 to 1.06; one-sided P = .046) and neratinib (HR, 0.72; 95% CI, 0.50 to 1.02; one-sided P = .033) relative to the control arm but there was no PFS benefit with CC-115 (one-sided P = .523). None of the experimental therapies demonstrated a significant OS benefit ( P > .05). CONCLUSION The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.
The effect of plasma exchange on serum levels of lacosamide: A case report
Peters, Bradley J. , Brown, Andrew E. , Thornton, Nathaniel M, Chalmers, Sarah , Chalmers, Sarah J, Thornton, Nathaniel M, Winters, Jeffrey L.

Mayo Clinic

American Journal of Health-System Pharmacy | September 15, 2023 | Volume: 80 | Issue: 24 | Pages: 1781-1786

10.1093/ajhp/zxad224 | PMID 37712141 Get It

Abstract Purpose We describe the case of a 22-year-old male who developed thyroid storm necessitating therapeutic plasma exchange (TPE). The patient’s past medical history was complicated by epilepsy, for which he took lacosamide. Little evidence was available to guide lacosamide dosing during TPE. Because of an exacerbation of the patient’s underlying epilepsy in the context of the thyroid storm, we conducted therapeutic medication monitoring of lacosamide concentrations to guide management. Summary We arranged for measurement of the lacosamide concentration immediately before TPE (5.1 μg/mL) and 2.5 hours after the initial measurement (3.4 μg/mL) to determine the amount of lacosamide removed by TPE. Utilizing population pharmacokinetic parameters, we calculated the expected concentration and compared this to the measured concentration. The difference between these values was used to determine the percentage removed via TPE compared to the expected post-TPE concentration. We found that one TPE session removed an additional 20% of serum lacosamide. Conclusion TPE appeared to remove an additional 20% of lacosamide when compared to the expected post-TPE concentration.
Consultation patterns before and after embedding pediatric palliative care into a pediatric hematology/oncology clinic
Greenmyer, Jacob R. , Ngo, Tiffany , Smith, Melissa M. , Collura, Christopher A. , Schiltz, Brenda , McCarthy, Sarah R. , McCarthy, Sarah , Smith, Melissa, Collura, Christopher, McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Pediatric Blood & Cancer | September 15, 2023 | Volume: 70 | Issue: 12 | Pages: No page available

10.1002/pbc.30663 | PMID 37710331 Get It

AbstractIntroductionPalliative care is a critical component of pediatric oncology care. Embedded pediatric palliative care (PPC) is relatively new in pediatric hematology/oncology (PHO) and may improve access, utilization, and quality of PPC. In June 2020, the Mayo Clinic PPC service transitioned from an afternoon, physically independent clinic to an all‐day clinic embedded within PHO.MethodsRetrospective chart review was used to quantify consultation rates from PHO to PPC in 12‐month study periods before and after establishment of an embedded clinic. Changes in descriptive statistics and consult patterns were calculated. Study periods were compared using either chi‐square or Fisher's exact tests for categorical variables and Wilcox rank sum tests for continuous variables.ResultsThere was an 89% increase in consultations from PHO to PPC after initiation of an embedded clinic (n = 20 vs. n = 38 per 12 months). The absolute number of completed outpatient consults increased from three (15% of visits) pre‐embedment to fourteen (37%) post‐embedment (p = .082). The median number of days from first oncology visit to PPC assessment was unchanged after embedment (36 vs. 47 days, p = .98). Consults for solid tumors increased from 22% (n = 4) pre‐embedment to 60% (n = 18) post‐embedment (p < .05). Consults for symptom management increased from 60% (n = 12) to 87% (n = 33) (p < .05).ConclusionsEmbedment of PPC into a PHO workspace was associated with an increased number of total consults, outpatient consults, solid tumor consults, and consults for symptom management. Our “partial‐PPO” model allowed for provision of PPC in the outpatient oncology setting in a clinic where there is not enough volume to support a full‐time oncology‐focused clinician team.